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994 The Journal of Thoracic and CardioObjective: Experience with the Carpentier-Edwards supra-annular porcine biopros-
thesis (Edwards Lifesciences, Irvine, Calif) has been evaluated longitudinally over
20 years. Clinical performance was evaluated by actuarial and actual analysis.
Hemodynamic performance was evaluated by echocardiographic/Doppler assess-
ment. Morphology of structural failure was evaluated from pathologic examinations.
Methods: From 1981 through 1999, 1823 patients (mean age, 68.9  10.9 years;
range, 19-89 years) underwent 1847 procedures. Concomitant coronary artery
bypass was performed in 788 (42.7%) patients. Previous valve procedures were
performed in 107 (5.8%) patients, and other cardiac procedures were performed in
87 (4.7%) patients.
Results: The overall valve-related complication rate was 4.36% per patient-year
(630 patients), with a fatality rate of 0.96% per patient-year (139 patients). Patient
survival at 18 years was 15.8%  1.6%. Overall late mortality rate was 6.3% per
patient-year. Overall actual cumulative freedom at 18 years from reoperation was
85.0%  1.2%, valve-related mortality was 88.7%  1.1%, and valve-related
residual morbidity was 96.3%  5.0%. Actual freedom from structural valve
deterioration at 18 years was 86.4%  1.2% overall, 90.5%  1.8% for age 61 to
70 years, and 98.2%  0.6% for age greater than 70 years. Structural valve
deterioration presented with pathologic evidence consistent with stenosis in 27.6%
and insufficiency in 72.4%. Hemodynamic performance at 1 year revealed normal
effective orifice area indexes for sizes 23 to 27 mm and mild-to-moderate reduction
for size 21 mm.
Conclusions: The Carpentier-Edwards supra-annular aortic porcine bioprosthesis con-
tinues to provide excellent freedom from structural valve deterioration and overall
freedom from valve-related residual morbidity, mortality, and reoperation up to 18
years. Hemodynamic performance is satisfactory. The prosthesis remains recommended
for patients older than 70 years and for patients 61 to 70 years of age, especially when
comorbid risk factors are not anticipated to provide extended survival.
The Carpentier-Edwards supra-annular (CE-SAV; Edwards Lifesciences, Ir-vine, Calif) aortic porcine bioprosthesis was introduced in 1981. Thissecond-generation porcine bioprosthesis has the tissue fixed with glutaral-
dehyde at 2 mm Hg, is initially treated with polysorbate 80, and is subsequently
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CDtreated with the combination of polysorbate 80 and ethanol,
calcium mitigation agents. The most extensive worldwide
experience with this bioprosthesis has been documented
from the University of British Columbia.1,2
This report extends the experience with the CE-SAV in
aortic valve replacement to 20 years. This documentation
will facilitate future comparison with other second- and
third-generation porcine and pericardial bioprostheses.
Patients and Methods
The CE-SAV was implanted in 1823 patients (1847 procedures)
for aortic valve replacement from 1981 through 1999 at the affil-
iated teaching hospitals of the University of British Columbia,
namely St Paul’s Hospital, Vancouver General Hospital, and
Royal Columbian Hospital. The mean age of the patient population
was 68.9  10.9 years (range, 19-89 years). Of the total popula-
tion, 5.8% (107) had previous valve procedures, and 4.7% (87) had
other cardiac procedures. Concomitant coronary artery bypass
(CAB) was performed in 42.7% (788).
The patient population was evaluated as an overall patient
cohort and by age distribution: 50 years or less, 133 procedures
(7.2%); 51 to 60 years, 230 (12.5%); 61 to 70 years, 579 (31.3%);
and more than 70 years, 905 (49.0%) procedures.
The total cumulative follow-up was 14,435.3 patient-years,
with a mean  SD of 7.82  4.82 years. The follow-up by age
categories was as follows: 50 years or less, 1377.6 patient-
years; 51 to 60 years, 2217.5 patient-years; 61 to 70 years,
4989.2 patient-years; and more than 70 years, 5850.9 patient-
years. The total follow-up was 97.4% complete during a
6-month closing interval in 2002.
The “Guidelines for Reporting Morbidity and Mortality After
Cardiac Valvular Operations” was used to define valve-related
complications and served as a basis for our methodology.3 Multi-
variate proportional hazard regression analysis was used to assess
risk factors (age [continuous and age categories 50, 51-60,
61-70, and70 years], sex, rhythm, previous CAB, previous valve
procedure, concomitant CAB, and valve size) as independent
predictors of structural valve deterioration (SVD), prosthetic valve
endocarditis (PVE), nonstructural dysfunction (NSD), valve-
related reoperation, valve-related residual morbidity (permanent
functional or neurologic impairment), and valve-related mortality.
The composites of valve-related complications are inclusive of
SVD, NSD, thromboembolism, hemorrhage (antithromboembolic-
related hemorrhage [ATH]), and PVE.
Patient survival was assessed by Kaplan-Meier actuarial meth-
ods. SVD and composites of valve-related complications were
evaluated by both actuarial and actual (cumulative incidence)
methods. The actual cumulative incidence and risk probabilities
were determined by an analog of the Kaplan-Meier method.
The overall longitudinal evaluation, conducted periodically,
incorporated a prospective hemodynamic study commencing in
1990 and a retrospective study in 1999. The studies included a
transthoracic echocardiographic/Doppler assessment at approxi-
mately 1 year postoperatively. The echocardiographic examina-
tions documented the following variables: mean pressure gradient,
peak pressure gradient, effective orifice area (calculated by the
continuity equation), effective orifice area index (effective orifice
The Journal of Thoraciarea divided by body surface area), cardiac output, cardiac index
(cardiac output divided by body surface area), and presence and
degree of regurgitation.
The operative and pathologic reports were evaluated to sum-
marize the morphology of the structural failure of the documented
failed prostheses. The reports facilitated classification as calcifi-
cation without leaflet tears, calcification with leaflet tears, primary
tears, and stent post dehiscence. The sites of the primary tears were
classified as commissural, middle and belly of the leaflet, basal
portion of the leaflet, and free margin of the leaflet.
This article has been formulated from the University of British
Columbia Cardiac Valve Database, and the investigators have
maintained University of British Columbia Clinical Research Eth-
ics Board approval throughout the years, which is currently effec-
tive to January 2006. The approval incorporates an informed
consent process.
Results
The early mortality was 5.0% (93/1847 procedures). The
early mortality with CAB was 5.6% (44/791 procedures)
and without CAB was 4.6% (49/1056 procedures). The late
mortality was 6.3% per patient-year. The overall survival at
15 years was 28.8%  1.5%, at 18 years was 15.8% 
1.6%, and at 20 years was 6.8%  2.0%.
The linearized occurrence rates of valve-related compli-
cations was 4.36% per patient-year (630), whereas the fa-
tality rate was 0.96% per patient-year (139 patients). The
linearized occurrence rates for valve-related complications
were as follows: PVE, 0.36% per patient-year (52); NSD,
0.24% per patient-year (34); ATH, 0.53% per patient-year
(76); overall thromboembolism, 2.33% per patient-year
(336); and major thromboembolism, 1.27% per patient-year
(183). Composites of valve-related complications were as
follows: valve-related reoperation, 1.12% per patient-year
(161); valve-related residual morbidity, 0.40% per patient-
year (58); and valve-related mortality, 0.96% per patient-
year (139).
The freedoms from SVD, both actuarial and actual, are
designated in Figures 1 and 2. There were 132 events for the
overall cohort. Actuarial and actual freedom at 18 years was
64.0% 3.6% and 86.4% 1.2%, respectively. For the 61-
to 70-year age group, the actuarial and actual freedom from
SVD was 77.6%  4.9% and 90.5%  1.8%, respectively,
and for the greater than 70-years age group, it was 94.6%
2.3% and 98.2%  0.6%, respectively. The number of
events of age categories is detailed by age groups in Table
1, documenting linearized rates and related fatalities and
reoperations. There were a total of 132 events with 26
fatalities and 109 reoperations with 6 fatalities (5.5%).
There were 23 documented events that did not have reop-
erations, with 22 fatalities, 20 attributed primarily to SVD.
The fatalities were contributed to by congestive heart fail-
ure, myocardial infarction, cardiac arrest, cancer, left ven-
tricular dysfunction and mitral regurgitation, renal failure,
c and Cardiovascular Surgery ● Volume 130, Number 4 995
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hemorrhage, and nonvalve-related cerebrovascular accident.
The actuarial freedom at 18 years from other valve-
related complications was as follows: PVE, 92.1%  2.4%
(actual, 96.3%  0.6%); NSD, 88.6%  5.6% (actual,
96.7%  0.8%); ATH, 88.9%  1.9% (actual, 94.1% 
0.7%); overall thromboembolism, 66.0%  5.1% (actual,
80.7%  1.3%); and major thromboembolism, 85.2% 
1.4% (actual, 90.0%  0.8%).
There were 139 mortalities from valve-related complica-
tions and 161 reoperations with 8 fatalities. Of the total 139
valve-related mortalities, 26 were due to SVD, 21 were due
Figure 1. Actuarial freedom froFigure 2. Actual freedom from SVD
996 The Journal of Thoracic and Cardiovascular Surgery ● Octoto PVE, 3 were due to NSD, 23 were due to ATH, and 66
were due to thromboembolism, with no cases of thrombosis.
Of the valve-related reoperations, there were 109 due to
SVD, 18 due to PVE, and 30 due to NSD, with 6, 1, and 1
fatalities, respectively.
The freedoms from valve-related composites (reopera-
tion, mortality, and residual morbidity) by age categories
are summarized at 18 years and designated time intervals in
Table 2.
The predictors of SVD were age (hazard ratio [HR],
0.96; P  .001), male sex (HR, 1.75; P  .0255), and
concomitant CAB (HR, 0.58; P  .0256). Age (HR, 0.97;
D overall and by age groups.m SVoverall and by age groups.
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NSD were age (HR, 0.96; P .01) and male sex (HR, 1.29;
P  .001). The predictors of valve-related reoperation were
age (HR, 0.95; P  .001) and concomitant CAB (HR, 0.48;
P  .0022). The only predictor of valve-related mortality
was age (HR, 1.04; P  .001). The predictors of valve-
related residual morbidity were age (HR, 1.05; P  .003)
and cardiac rhythm (atrial fibrillation or paced; HR, 2.1;
P  .0442).
The mean time from implantation to reoperation for SVD
was not different (P  .278) by age categories: 50 years or
less, 11.8  3.1 years (47); 51 to 60 years, 11.2  3.4 years
(39); 61 to 70 years, 11.5  3.8 years (18); and more than
70 years, 8.8  2.9 years (5).
The pathology of the 132 cases of SVD was reviewed. Of
the 132 cases of SVD, 109 came to reoperation, 18 others
were noted at autopsy, and 5 were confirmed by echocar-
diography. The pathology of 127 SVDs, 109 reoperations
and 18 autopsies, revealed the following findings: calcifi-
cation with leaflet tear, 78 (61.4%); calcification without
accompanying leaflet tear, 29 (22.8%); primary tears, 19
(15.0%); and stent post dehiscence, 1 (0.78%). Of the pri-
mary tears, the location of the lesions were commissural
(11), free margin (7), basal (1), and unknown (4), and there
was often more than one tear per valve. The degree of
calcification was graded as mild in 22, mild to moderate in
30, moderate to severe in 29, and unknown in 27, for a total
of 108 valves with calcification as a component. The loca-
tion of the calcification was at the commissures in 44,
TABLE 1. Structural valve deterioration documented overal
fatal, and reoperation and no reoperation, alive and fatal
Age groups Rates (%/pt-y) Total events
50 3.7 51
51-60 1.94 43
61-70 0.56 28
70 0.17 10
Total 0.91 132
pt-y, Patient-years. *SVD fatalities are shown in parentheses, non-SVD fa
TABLE 2. Freedom from valve-related composites of comp
Age groups
VR-REOP
Actuarial Actual Ac
Total 62.3 3.5 85.0  1.2 94
50 27.9 5.7 44.8  4.9
51-60 43.7 6.4 64.2  3.9 97
61-70 79.8 4.7 91.1  1.7 94
70 96.6 1.3 98.4  5.1 91VR-REOP, Valve-related reoperation; VR-MORB, valve-related residual morbidity
The Journal of Thoracimiddle-belly in 12, free margins in 33, as known in 66
patients, with often more than one location affected. The
pathologic lesions created stenosis in 35 (27.6%) and aortic
insufficiency in 92 (72.4%).
The distribution of the SVD lesions changed throughout
the age groups: 50 years or less, 46; 51 to 60 years, 44; 61
to 70 years, 28; and greater than 70 years, 9. This broke
down as follows: calcification with tears, 78%, 59%, 50%,
and 22%, respectively; calcification without tears, 13%,
23%, 32%, and 44%, respectively; and primary tears, 9%,
18%, 14%, and 33%, respectively. The one case of stent
post dehiscence occurred in the 61- to 70-years age group
(4%).
Of the 5 SVDs diagnosed on the basis of clinical param-
eters and echocardiography, echocardiograms showed 3 cal-
cifications without tears with severe stenosis and 2 primary
tears showing mild and moderate degrees of stenosis and
moderate and severe degrees of insufficiency.
The hemodynamic evaluation was performed in 2 struc-
tured studies in 1990 (39 patients) and 1999 (19 patients) at
the 1-year interval. Complete echocardiographic data is
detailed on 45 of the 56 patients in Table 3. The number of
evaluations were as follows: 19 mm, 5; 21 mm, 11; 23 mm,
17; 25 mm, 16; 27 mm, 6; and 29 mm, 1. The reliability of
the 19-mm parameters to clinical practice might not be
appropriate: mean gradient, 17.3  2.6 mm Hg; peak gra-
dient, 29.7  15.8 mm Hg; effective orifice area, 0.75 cm2;
effective orifice area index, 0.47 cm2/m2; cardiac output, 3.9
L/min; and cardiac index, 2.4 L/min/m2. The echocardio-
by age groups by linearized rates, events, events alive and
Events
Reoperation No reoperationve Fatal
6 5 47 (1)* 4 (4)*
8 5 39 (1) 4 (4)
6 12 18 (4) 10 (8) [1]
6 4 5 (0) 5 (4) [1]
6 26 109 (6) 23 (20) [2]
s in brackets.
ions (actuarial and actual) by age groups at 18 years
VR-MORB VR-MORT
al Actual Actuarial Actual
8.2 96.3  5.0 78.4 2.9 88.7  1.1
— 86.0  4.7 88.3  3.8
1.2 97.6  1.1 91.8 2.7 93.9  1.9
1.3 95.9  0.9 76.6 5.6 88.1  2.0
2.2 95.5  0.8 67.6 8.6 87.5  1.5l and
Ali
4
3
1
10licat
tuari
.6 
—
.3 
.5 
.4 ; VR-MORT, valve-related mortality.
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ial-mild regurgitation, 1.7% (1) with moderate regurgita-
tion, and the remaining 80.4% (45) with no regurgitation. In
7.1% (4) regurgitation was not reported.
Discussion
The Carpentier-Edwards SAV porcine bioprosthesis is the
longest-standing bioprosthesis of the current second- and
third-generation porcine and pericardial bioprostheses. The
CE-SAV was introduced in the early 1980s with advanced
tissue preservation and calcium mitigation therapy to reduce
the incidence of SVD. The CE-SAV was designed for
supra-annular implantation to optimize hemodynamics over
that of the first-generation intra-annular bioprostheses. The
CE-SAV is formulated with tissue fixed with glutaraldehyde
at a pressure of approximately 2 mm Hg. The antimineral-
ization treatment of the CE-SAV bioprosthesis encompasses
the detergent agent polysorbate 80 and the addition of ethanol
into the XenoLogiX treatment (Edwards Lifesciences). These
treatments were commenced in the early 1980s.
The use of bioprostheses for aortic valve replacement has
been considerably extended in the past 5 years, with im-
proved stented bioprostheses and the introduction of stent-
less bioprostheses. This trend from the use of mechanical
prostheses has been fostered by the knowledge of advanced
age being protective from SVD, as well as the advancing
age of the population with degenerative aortic valve disease.
The important concerns of aortic bioprostheses are the
extent of durability and the hemodynamic capability to
avoid detrimental patient-prosthesis mismatch. This evalu-
ation of the CE-SAV bioprosthesis has addressed both these
issues. The second issue of patient-prosthesis mismatch and
its prevention has been extensively evaluated by Pibarot and
Dumesnil.4
This second-generation aortic porcine bioprosthesis (CE-
SAV) has been evaluated periodically since the commence-
ment of its use in late 1981.1,2 This report has provided the
opportunity to evaluate performance to predominantly 18
years. The actual freedom from SVD for patients more than
70 years of age was 98% (actuarial, 95%), and for patients
61 to 70 years of age, actual freedom from SVD was 91%
TABLE 3. Hemodynamic evaluation at the 1-year interval
Variable 21 mm (8)*
Mean gradient (mm Hg) 14.2 5.3
Peak gradient (mm Hg) 26.6 13.4
EOA (cm2/cm2) 1.46 0.57
EOA index (cm2/m2) 0.85 0.34
Cardiac output (L/min) 5.0 1.9
Cardiac index (L/min/m2) 2.9  1.0
EOA, Effective orifice area. *Number of patients is shown in parentheses(actuarial, 78%). The diagnosis of SVD was made at the
998 The Journal of Thoracic and Cardiovascular Surgery ● Octotime of reoperation or autopsy or echocardiographically in
patients with reducing functional class. Of the 132 failed
prostheses in 1823 patients, 109 prostheses were explanted
for SVD; 18 were identified at autopsy, and 5 were identified
on the basis of clinical and echocardiographic parameters.
The remaining currently marketed aortic bioprostheses
of the second and third generations have commencement of
use and reporting of shorter duration. These prostheses are
the following: Carpentier-Edwards PERIMOUNT, Sorin
Pericarbon pericardial, Hancock II, St Jude Medical Epic
(formerly Biocor), and Medtronic Mosaic porcine biopros-
thesis, as well as the new stentless configurations, namely St
Jude Medical Toronto SPV, Medtronic Freestyle, Edwards
Prima Plus, and Sorin Freedom. The published durability of
the stented bioprostheses is summarized in Table 4.5-14 The
identification of SVD does vary between studies from di-
agnosis at explantation for the Carpentier-Edwards PERI-
MOUNT pericardial bioprosthesis by Frater and associ-
ates10 and Banbury and colleagues11 to the current study on
the Carpentier-Edwards SAV porcine bioprosthesis by explan-
tation, autopsy, and clinical assessment confirmed by echocar-
diography. Follow-up of the stentless porcine bioprostheses is
now only nearing the time interval when structural failure was
identified with the stented bioprostheses.
A comparison of the aortic CE-SAV and the CE-
PERIMOUNT was conducted by Jamieson and col-
leagues.15 Actual freedom from SVD at 15 years was 99.6%
and 98% for patients more than 70 years of age for the
CE-PERIMOUNT and the CE-SAV, respectively; 99% and
93% for patients 66 to 70 years of age, respectively; and
86% and 92% for patients 61 to 65 years of age, respec-
tively. The freedom from SVD for the 61- to 70-year age
group was 93% for both the CE-SAV and the CE-PERI-
MOUNT. The diagnosis of SVD with the CE-SAV at the
University of British Columbia is documented above,
whereas the Francois Rabelais University diagnosis was
with stenotic or regurgitant symptoms or asymptomatic with
a mean gradient of greater than 40 mm Hg or insufficiency
of grade III-IV. These reports of the CE-PERIMOUNT
documented that calcification stenosis was the predominant
23 mm (15) 25 mm (16) 27 mm (6)
14.9 7.0 13.9 5.2 8.5  2.6
28.6  12.3 27.9 9.7 16.7  4.7
1.48 0.52 1.37 0.41 1.91  0.72
0.83 0.39 0.70 0.21 0.98  0.41
5.3 1.8 5.0 1.6 4.7  2.2
3.0 1.3 2.6 0.8 2.4  1.2mode of failure. This study has revealed that the mode of
ber 2005
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74% by insufficiency with or without calcification.
The documented studies identified that the CE-SAV and
CE-PERIMOUNT aortic prostheses do not perform differ-
ently in contradistinction to the mitral prostheses. In 1999,
the author reported a greater incidence of structural failure
TABLE 4. Summary of reported freedom from structural
pericardial bioprostheses
Author Prosthesis Mean age (y)
David and coworkers5 Hancock II 65 12
Rizzoli and coworkers6 Hancock II 67 8
Jamieson and coworkers7 CE-SAV 67.6 11.2
Hancock II 65.2 2.1
Myken and coworkers8 SJM Biocor 69
Jamieson and coworkers9 MM 70.5 10.7
Frater and coworkers10 CE-P* 64.9 11.8
Banbury and coworkers11 CE-P* 65 12
Aupart and coworkers12 CE-P 67.5 11.2
Neville and coworkers13 CE-P 68.3 10.8
Dellgren and coworkers14 CE-P 71.3 8.8
Jamieson and coworkers
(current study)
CE-SAV 68.9 10.9
CE-P, Carpentier-Edwards PERIMOUNT pericardial; MM, Medtronic Mosaic
Supra-Annular porcine. *Diagnosed at explantation.with the mitral CE-SAV.16 The actual freedom from SVD at
The Journal of Thoraci10 years was as follows: 41 to 50 years, 92% versus 70%;
51 to 60 years, 90% versus 80%; 61 to 70 years, 97% versus
88%; and older than 70 years, 100% versus 97%, respec-
tively. It was considered that the low-profile configuration
of the CE-SAV mitral prosthesis contributed to altered
stress and the accelerated failure mode.15 This accelerated
ve deterioration of predominant marketed porcine and
e group (y)
Freedom from SVD
Time interval (y)Actuarial (%) Actual (%)
81 5 15
65 100 15
65 76 6 15
88.9  6.2 92.4 3.3 15
65 93.2 4.8 15
65 92 4.5 15
69.5 3.1 85.7 1.3 15
70 96.9 1.5 98.8 0.5 15
66-70 87.0 6.0 93.6 2.3 15
65 54.2 4.1 68.8 2.8 15
65 91.5 2.9 96.4 1.0 15
83.2 4.8 88.1 3.2 15
70 100 100 15
66-70 100 100 15
65 75.1 6.3 78.5 5.4
65 100 100 15
76.0 7 15
61-70 83.0 5 15
71-80 99 15
80 100 15
99.7 0.3 99.8 0.2 6
85.1 3.0 94.4 14
65 96.3 2.1 98.7 14
65 76.1 5.0 88.2 14
77 15
96  4 10
94 12
60 98 12
60 89 12
86  9 92  6 12
74.9 2.3 88.9 1.0 15
70 94.6 2.3 98.2 0.6 15
61-70 85.7 3.2 92.8 1.5 15
51-60 62.6 5.4 75.4 3.6 15
50 44.0 5.8 56.5 4.9 15
64.0 3.6 86.4 1.2 18
70 94.6 2.3 98.2 0.6 18
61-70 77.6 4.9 90.5 1.8 18
51-60 51.0 7.0 70.6 4.0 18
50 31.9 6.3 48.4 5.3 18
ine; SJM, St Jude Medical Biocor (now Epic); CE-SAV, Carpentier-Edwardsval
Ag
porcfailure mode has not been evident with the CE-SAV aortic
c and Cardiovascular Surgery ● Volume 130, Number 4 999
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PERIMOUNT mitral device by reporting colleagues in
2001 has confirmed the clinical performance of the prosthe-
sis.17 The experience of the Carpentier-Edwards SAV mitral
porcine bioprosthesis is worthy of further documentation.
The hemodynamic performance of aortic prostheses gen-
erally is recognized as being instrumental in regression of
left ventricular mass and probably increasing survival.
Pibarot and Dumesnil4 have researched the concept of
patient-prosthesis mismatch, identifying that the normal ef-
fective orifice area index is 0.85 cm2/m2 or greater. Severe
obstructive features of a prosthesis correlate with an effec-
tive orifice area index of less than 0.65 cm2/m2. The hemo-
dynamic performance of the implanted aortic prostheses
should be optimized by consideration of reference in vivo
effective orifice area and the basal surface area to achieve
the anticipated indexed effective orifice area to avoid det-
rimental patient-prosthesis mismatch.4 The CE-SAV bio-
prosthesis can provide satisfactory hemodynamics in all
valve sizes, except possibly 19 mm, for which inadequate
data are available. The suprastructure and fine sewing cuff
of the prosthesis together with the supra-annular nonevert-
ing implantation technique should provide optimization of
hemodynamics. The new extended supra-annular biopros-
thesis configurations, namely the Carpentier-Edwards PERI-
MOUNT Magna, Sorin Soprano, and Mitroflow, are likely
to play a significant role in the small aortic root to prevent
unacceptable patient-prosthesis mismatch.
The CE-SAV porcine bioprosthesis has excellent dura-
bility approaching 20 years and is recommended for patients
older than 70 years, as well as for 61- to 70-year-old
patients, especially if comorbidity is likely to compromise
anticipated life expectancy. The CE-SAV can be considered
the gold standard to which other second- and third-
generation bioprostheses can be compared.
We appreciate the word processing of the manuscript by Kevin
Shillitto.
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